symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
TLSA,0.731,0,642893,73530559,0,0.5-1.39,-0.119,Tiziana Life Sciences Ltd,USD,0001723069,BMG889121031,88875G101,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.tizianalifesciences.com,"Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.","Mr. Gabriele Marco Antonio Cerrone M.B.A., MBA",Healthcare,GB,9,44 20 7495 2379,55 Park Lane,London,,W1K 1NA,0.387211,1.40721,https://financialmodelingprep.com/image-stock/TLSA.png,2018-11-20,False,False,True,True,False
